Literature DB >> 32926263

Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet's Disease with Intestinal Involvement and Crohn's Disease.

Fatma Alibaz-Oner1, Rabia Ergelen2, Ilkay Ergenc3, Gizem Seven4, Ayten Yazıcı5, Ayse Cefle5, Cemal Bes6, Ozlen Atug3, Haner Direskeneli4.   

Abstract

BACKGROUNDS: Behçet's disease (BD) and Crohn's disease (CD) cannot be easily differentiated in young adults presenting with nonspecific gastrointestinal (GI) manifestations due to similar extraintestinal manifestations. We recently showed that increased common femoral vein (CFV) thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases with a specificity higher than 80% for the cutoff value of ≥ 0.5 mm. We suggest that CFV thickness measurement with ultrasonography (US) can be a diagnostic tool for BD. AIMS: To assess the diagnostic performance of CFV thickness measurement in the differential diagnosis of BD and CD.
METHODS: Patients with BD (n = 69), CD (n = 38), and healthy controls (HC) (n = 38) were included in the study. Bilateral CFV thickness was measured with Doppler US.
RESULTS: Both right and left CFV thicknesses were significantly higher in BD compared to HC and CD (for right: 0.76 mm vs 0.33 mm, for left: 0.78 mm vs 0.35 mm, p < 0.001 for both). CFV thicknesses in CD were similar to HC (p > 0.05 for both). CFV thickness was also similar between BD patients with and without GI involvement (p = 0.367). The diagnostic cutoff values of ≥ 0.5 mm for CFV thickness performed well against to both CD and HCs for discrimination of BD. The sensitivity and specificity rates were > 85% for both HC and CD. Positive and negative predictive values in our tertiary clinical setting were > 90%.
CONCLUSION: We found significantly lower CFV thickness in CD compared to BD. Our results suggest that CFV wall thickness measurement is a distinctive diagnostic tool for the differentiation of BD and CD and can be helpful in daily practice for the differentiation of two diseases.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Behçet’s disease; Crohn’s disease; Diagnostic; Differential diagnosis; Ultrasound; Vein wall thickness

Year:  2020        PMID: 32926263     DOI: 10.1007/s10620-020-06587-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  5 in total

1.  Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement.

Authors:  Sinem Nihal Esatoglu; Ibrahim Hatemi; Yesim Ozguler; Gulen Hatemi; Hafize Uzun; Aykut Ferhat Celik; Hasan Yazici
Journal:  Clin Exp Rheumatol       Date:  2018-12-13       Impact factor: 4.473

2.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome.

Authors:  I Fresko; S Ugurlu; F Ozbakir; A Celik; S Yurdakul; V Hamuryudan; H Yazici
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

3.  Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score.

Authors:  Sedat Yilmaz; Ismail Simsek; Muhammet Cinar; Hakan Erdem; Osman Kose; Yusuf Yazici; Salih Pay
Journal:  Clin Exp Rheumatol       Date:  2013-09-09       Impact factor: 4.473

4.  Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease.

Authors:  I Hatemi; G Hatemi; A F Celik; M Melikoglu; N Arzuhal; C Mat; Y Ozyazgan; H Yazici
Journal:  Clin Exp Rheumatol       Date:  2008 Jul-Aug       Impact factor: 4.473

5.  Comparison between Intestinal Behçet's Disease and Crohn's Disease in Characteristics of Symptom, Endoscopy, and Radiology.

Authors:  Tianyu Zhang; Liwen Hong; Zhengting Wang; Rong Fan; Maochen Zhang; Yun Lin; Mengmeng Cheng; Xiaolin Zhou; Peijun Sun; Xiaoyi Lin; Jie Zhong
Journal:  Gastroenterol Res Pract       Date:  2017-05-31       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.